
Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

Redeye comments on Active Biotech's second quarter report. The protocol for the myelofibrosis study is being updated. The biodistribution study of laquinimod finished with excellent results. The company is looking for a partner as the next step.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal